Endometriosis Opportunity CiceroDx offers ReceptivaDx for endometriosis, addressing a large unmet need and long diagnostic delay, presenting a ready-made entry point for hospital systems, fertility clinics, and OB-GYN networks seeking validated diagnostic tools.

Global Test Launch ReceptivaDx is positioned as a global test for all endometriosis stages, enabling cross-border sales opportunities, collaborations with international hospitals, and potential partnerships with global distributors serving women's health markets.

NIH Validation NIH funding history reinforces credibility; pursue expanded grant-supported studies and new research collaborations to accelerate adoption, create co-branded programs with academic centers, and open doors to grant-funded procurement channels.

Infertility Focus Target fertility clinics and IVF centers given the product’s alignment with unexplained infertility and recurrent pregnancy loss, offering complementary diagnostic solutions that can shorten time-to-diagnosis and inform treatment pathways.

Growth Readiness With modest revenue and small team size, position CiceroDx as a scalable partner for large healthcare networks through channel partnerships, OEM collaborations, and managed service arrangements that leverage existing diagnostic infrastructures.